Citigroup Inc Ikena Oncology, Inc. Transaction History

Citigroup Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.24 - $1.82 $990 - $1,454	-799 Reduced 13.77%	5,005 $8,000
Q1 2024 May 10, 2024	BUY	$1.27 - $2.0 $1,489 - $2,346	1,173 Added 25.33%	5,804 $8,000
Q4 2023 Feb 09, 2024	BUY	$1.33 - $4.4 $6,145 - $20,332	4,621 Added 46210.0%	4,631 $9,000
Q3 2023 Nov 09, 2023	SELL	$4.09 - $6.43 $25,852 - $40,644	-6,321 Reduced 99.84%	10 $0
Q2 2023 Aug 10, 2023	BUY	$3.5 - $7.31 $7,094 - $14,817	2,027 Added 47.1%	6,331 $41,000
Q1 2023 May 11, 2023	BUY	$2.62 - $4.97 $9,439 - $17,906	3,603 Added 513.98%	4,304 $14,000
Q4 2022 Feb 09, 2023	BUY	$2.0 - $3.7 $44 - $81	22 Added 3.24%	701 $1,000
Q3 2022 Nov 10, 2022	SELL	$3.46 - $6.0 $889 - $1,542	-257 Reduced 27.46%	679 $2,000
Q2 2022 Aug 10, 2022	SELL	$3.23 - $7.4 $8,087 - $18,529	-2,504 Reduced 72.79%	936 $4,000
Q1 2022 May 12, 2022	SELL	$5.61 - $13.85 $31,511 - $77,795	-5,617 Reduced 62.02%	3,440 $21,000
Q4 2021 Feb 10, 2022	BUY	$10.52 - $16.96 $80,919 - $130,456	7,692 Added 563.52%	9,057 $114,000
Q3 2021 Nov 10, 2021	BUY	$9.82 - $15.23 $13,404 - $20,788	1,365 New	1,365 $17,000

30.4M

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $55.1M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.